Ken Cacciatore
Stock Analyst at TD Cowen
(0.34)
# 4,309
Out of 5,170 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $22.91 | +118.25% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $5.03 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $18.11 | +10.44% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $16.17 | +116.45% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $4.69 | +966.12% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $5.30 | +843.40% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $8.96 | +402.23% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $15.10 | +2,946.36% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $22.91
Upside: +118.25%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.03
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $18.11
Upside: +10.44%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $16.17
Upside: +116.45%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $4.69
Upside: +966.12%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $5.30
Upside: +843.40%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $8.96
Upside: +402.23%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $15.10
Upside: +2,946.36%